Absstract of: WO2025147134A1
The present invention relates to a nanodisc comprising a virus receptor and a FC fragment. In addition, the present invention relates to a pharmaceutical composition for prevention or treatment of viral infection, the composition containing the nanodisc. In the present invention, the nanodisc comprising a virus receptor and a FC fragment of the present invention has been confirmed to have a long in vivo half-life while also exhibiting excellent antiviral efficacy.
Absstract of: WO2025146681A1
The present invention relates to pro-nano-emulsion compositions comprising at least one type of Omega 3 fatty acid capable of converting to nano-emulsion composition having average droplet size of below Ip, typically below 0.5p, and use thereof, particularly as dietary supplement, for preferential delivery of the Omega 3 fatty acid to heart and/or liver tissue of a subject consuming the composition, thereby maintaining normal cardiovascular/hepatic function and/or improving cardiovascular/hepatic disease or disorders.
Absstract of: WO2025146614A1
A nanofiber-based skin patch for alleviating pain, swelling, and inflammation comprising a skin adhesive layer, a nanofibrous layer comprising at least one macromolecule and a composition of natural active agents comprising a mint extract, a rose madder extract, a rosemary extract, a lavender extract, a clove extract, an arnica extract, a ginger extract, a sage extract, a ginseng extract, a garlic extract, curcumin, bromelain, honey, royal jelly, propolis, a non-woven layer configure to connect the nanofibrous layer to the skin adhesive layer such that the nanofibrous scaffold is fabricated on a top surface of non-woven layer, and a protective layer configure to protect the nanofibrous layer. The developed nanofiber-based skin patch can relieve pain, reduce swelling, and mitigate inflammation in different areas of a subject's bod without causing side effects.
Absstract of: WO2025146125A1
Disclosed in the present application are a compound having a structural formula as represented by formula (I), and a salt and an isomer thereof. Further disclosed in the present application is a nanoparticle composition containing the compound, or the salt thereof or the isomer thereof. The nanoparticle of the present application can efficiently deliver a drug or a vaccine into cells to exert the therapeutic or preventive purpose of the drug or the vaccine.
Absstract of: WO2025147545A1
The present disclosure relates to compositions comprising lipid nanoparticles for delivering nucleic acid molecules into cells. Also included are methods for producing and using such compositions.
Absstract of: EP4582089A2
The invention provides a composition comprising a biphasic particle, the biphasic particle comprising an alginate gel encapsulating an inhibitory RNA for use in improving cardiac function in a mammal, wherein the inhibitory RNA reduces expression of a polypeptide in which reduced expression of the polypeptide improves cardiac function, thereby improving cardiac function of the mammal, wherein the polypeptide is eotaxin-3, cathepsin-S, DK -1, follistatin, ST-2, GRO-a, IL-21, NOV, transferrin, TIMP-2, TNFaRI, TNFaRII, angiostatin, CCL25, ANGPTL4, or MMP-3.
Absstract of: EP4582410A1
The present invention provides a cationic lipid compound with high efficiency, low toxicity and stable expression, which is a compound of formula (I) or an N-oxide, a solvate, a pharmaceutically acceptable salt or a stereoisomer thereof. Further provided are a composition comprising the described compound and a use thereof in delivering a therapeutic or prophylactic agent.
Absstract of: CN119789852A
The present invention relates to lipid nanoparticle (LNP) compositions and therapeutic polynucleotides, such as TERT mRNA, which may be delivered in formulation with the LNP compositions for use in the prevention or treatment of pulmonary disease and/or fibrosis.
Absstract of: WO2024046999A1
The present invention relates to a novel type of composition for developing stable synthetic perfluoro-hydrocarbon-based oxygen carriers, the manufacturing thereof, and the use thereof as a synthetic blood and oxygen substitute carrier and as a volume replacement.
Absstract of: AU2023333536A1
Compositions and methods for making and using engineered NK cells, T cells and B cells that express a chimeric antigen receptor.
Absstract of: AU2023331445A1
The present application relates to indazole derivatives of general Formula (I), to processes for their preparation, to compositions comprising them and to their use in activation of a serotonin receptors in a cell, as well as to treating diseases, disorders or conditions by activation of a serotonin receptors in a cell. The diseases, disorders or conditions include, for example, psychosis, mental illnesses and CNS disorders. Formula (I) wherein Q is selected from (Q1), (Q2), (Q3), (Q4) (Q5) and (Q6)
Absstract of: AU2023334610A1
Novel ionizable lipids and lipid nanoparticles that can be used in the delivery of therapeutic cargos are disclosed.
Absstract of: AU2023334056A1
The present disclosure provides modified immune cells or precursors thereof comprising chimeric antigen receptors and surface-bound, biologically inert molecules. Also included are methods of preparing said modified immune cells and methods of treating CAR treatment-related toxicities in subjects in need thereof comprising said modified immune cells.
Absstract of: WO2025140596A1
The present invention provides an ionizable cationic lipid compound having a structure as represented by formula (I). The compound can be used for preparing lipid nanoparticles (LNPs) for delivery of a therapeutic agent and/or a preventive agent. The LNPs prepared using the ionizable cationic lipid compound of the present invention have high stability and transfection efficiency, and can efficiently and stably deliver biologically active substances (including a nucleic acid, such as mRNA) to target cells or organs, thereby inducing a highly specific antibody response in vivo.
Absstract of: CN120267630A
本发明公开了一种负载铁死亡抑制剂的仿生纳米载体及其应用。本发明以细菌囊泡和血小板膜采用挤出法得到杂化囊泡,在其内部负载铁死亡抑制剂Fer‑1,外部以化学偶联和物理插入的方式连接马来酰亚胺活化的尿激酶和DSPE‑PEG2000‑CREKA,得到最终制剂,该纳米载体将以多重共价靶向方式到达血栓部位并定点释放溶栓药物尿激酶和抗炎药物Fer‑1,达到精准溶栓和改善血栓微环境的效果。
Absstract of: CN120267638A
本申请涉及医用材料技术领域,尤其涉及一种曲安奈德颗粒的制备方法和含药微针递送系统的应用,通过开发一种新的曲安奈德给药方式实现药物的局部递送、缓释和更好的透皮吸收以及延长药物作用时间,有效治疗肉芽肿性乳腺炎。此外,微针阵列具有生物相容性好、药物释放可控、使用方便等优点,适用于肉芽肿性乳腺炎的局部治疗。
Absstract of: CN120267637A
本发明涉及一种PLLA‑PN包封纳米颗粒的制备方法、纳米颗粒及其应用,其制备方法包括以下步骤:将PN溶液进行超声处理,每进行4s超声后随即进行5s空置,持续5min后取出混匀一次,重复多次;将PLLA溶解于二氯甲烷中得到PLLA溶液;将前述超声处理后的PN溶液与PLLA溶液混合,再进行超声处理,每进行4s超声后随即进行5s空置,持续5min,得到混合液;向混合液内加入PVA溶液,进行超声处理,每进行4s超声后随即进行5s空置,持续2min;得到原料溶液;向得到的原料溶液内加入异丙醇溶液,搅拌挥发有机溶剂得到PLLA‑PN包封纳米颗粒溶液。本发明通过PLLA包封实现了PN的长效稳定缓释。
Absstract of: CN120267636A
本发明涉及纳米生物医药材料领域,具体公开了一种混合膜包覆的铜纳米系统及其制备方法和抗菌应用。所述的混合膜包覆的铜纳米系统采用红细胞膜和血小板膜同时包覆铜纳米颗粒而成。其制备方法包含如下步骤:将红细胞膜和血小板膜分散于溶剂A中,进行超声后得杂合膜;将过量的杂合膜与包覆铜纳米颗粒分散在溶剂B中,超声后去除多余的杂合膜,即得混合膜包覆的铜纳米系统。所述的混合膜包覆的铜纳米系统具有良好生物相容性,相比于传统生物膜抑制剂,在具有良好的抗生物被膜作用的基础上,具有优异的体外抗菌活性和较低的毒性,为铜纳米颗粒的研究和应用提供了一种新的途径。符合当今社会的发展要求,具有良好的应用和发展前景。
Absstract of: US2025179015A1
The present invention provides an ionizable lipid compound having an optimized carbon chain length and an amine head so that the ionizable lipid compound has increased delivery efficiency for an active molecule including, but not limited to, nucleic acids, proteins, small molecule drugs and the like. The present invention further relates to a lipid nanoparticle (LNP) comprising the ionizable lipid compound and the active molecule, and a pharmaceutical composition comprising the lipid nanoparticle.
Absstract of: CN120267633A
本发明公开了一种蛋白基纳米颗粒及其制备方法和应用。本发明的蛋白基纳米颗粒具有核‑壳结构,内核为负载有活性药物的玉米醇溶蛋白颗粒,外壳的组成包括胰蛋白酶抑制剂。本发明的蛋白基纳米颗粒的制备方法包括以下步骤:1)制备荷载活性药物的玉米醇溶蛋白分散液和壳层材料水溶液;2)将荷载活性药物的玉米醇溶蛋白分散液缓慢加入到搅拌状态的壳层材料水溶液中,再进行旋转蒸发和冷冻干燥。本发明的蛋白基纳米颗粒具有优异的抗胃肠道消化效果,可以有效地将各类疏水性活性药物递送至下消化系统,显著增强了荷载药物的稳定性和缓释效率,且该蛋白基纳米颗粒的生物相容性佳、安全无毒、制备工艺简单,适合进行大规模工业化生产和应用。
Absstract of: CN120271602A
本发明属于生物化学材料技术领域,具体公开了一种具有近红外一区(NIR‑I)吸收和近红外二区(NIR‑II)发射特性的I型光敏剂及其制备方法与应用。本发明所提供的光敏剂分子具有式I所示D‑π‑A分子结构,其中二噻吩并吡咯衍生物作为电子供体(Donor),苯并cd吲哚盐作为电子受体(Acceptor),通过单/双噻吩基π桥连接,采用Knoevenagel缩合反应制备而成。本发明所述I型光敏剂可在NIR‑I光源激发下发射出NIR‑II荧光,且具有优异的I型活性氧生成能力及光热产生能力,能够实现高信噪比的生物组织荧光成像检测以及乏氧条件下的高效光动力‑光热联合肿瘤治疗,在生物医药领域尤其是肿瘤诊疗方面具有巨大的潜在应用价值。
Absstract of: CN120267629A
本发明涉及药物技术领域,尤其涉及一种组合物及其在制备抗肿瘤药物中的应用。本发明组合物由康普瑞汀A1、康普瑞汀A4与白蛋白组成。纳米组合物的制备方法包括以下步骤:(1)将不同的白蛋白溶液用双蒸水稀释至不同的浓度;(2)将不同浓度的康普瑞汀A1、康普瑞汀A4分子与步骤(1)中的白蛋白溶液进行充分混匀;(3)将步骤(2)中的混合物在细胞超声破碎仪中以不同功率进行超声,离心后得到包含康普瑞汀A1、康普瑞汀A4的白蛋白纳米组合成。本发明提供了一种抗肿瘤纳米组合物的制备方法,方法简单,抗肿瘤效果显著,可以有效解决并克服pMMR型实体肿瘤对免疫治疗耐药等临床问题。
Absstract of: CN120267811A
本发明涉及活性超级抗原治疗男女性功能障碍复方生物注射制剂NF及制取方法,包括通用基础配方NF、男性用NF‑M和女性用NF‑F,所述通用基础配方NF包含以下组分及其参数:超级抗原突变体0.1‑0.5mg/mL、神经营养因子50‑100μg/mL、激素调节肽10‑20μg/mL和pH响应型脂质纳米颗粒8‑10mg/mL。该活性超级抗原治疗男女性功能障碍复方生物注射制剂NF及制取方法,通过激活T细胞表面的TCR‑Vβ链及APC的MHC‑II分子,诱导局部免疫调节而非全身性炎症反应,靶向改善生殖系统微循环及神经内分泌功能,采用超级抗原激活局部免疫细胞分泌血管内皮生长因子和NO,改善血流灌注,神经营养因子修复海绵体神经损伤,激素调节肽通过下丘脑‑垂体‑性腺轴间接调节性激素水平,适用于激素相关性功能障碍。
Absstract of: CN119654308A
The present disclosure provides one or more ionizable lipids and lipid nanoparticles comprising the same. The present disclosure also provides pharmaceutical compositions comprising lipid nanoparticles encapsulating an active agent.
Nº publicación: JP2025521148A 08/07/2025
Applicant:
シアトルチルドレンズホスピタルディー/ビー/エイシアトルチルドレンズリサーチインスティテュート
Absstract of: AU2023281726A1
Recombinant receptors with a binding domain that binds B cell activation factor receptor (BAFF-R) are disclosed. Recombinant receptors include chimeric antigen receptors (CAR) having an anti-BAFF-R binding domain, a transmembrane domain, a CD3ζ/4-1BB intracellular signaling domain, and a spacer. Methods and systems to treat BAFF-R-expressing cancers, such as mantle cell lymphoma (MCL), multiple myeloma (MM), acute lymphoblastic leukemia (ALL), and diffuse large B-cell lymphoma (DLBCL), are also provided. The recombinant receptors disclosed herein can bind and elicit cytotoxic effects even in low antigen density conditions.